NeuroBo Pharmaceuticals (NRBO) Competitors $2.73 +0.08 (+3.02%) (As of 10/4/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends NRBO vs. GLMD, SCYX, SNOA, SYRS, BRNS, CELU, ANEB, AFMD, AADI, and PRPHShould you be buying NeuroBo Pharmaceuticals stock or one of its competitors? The main competitors of NeuroBo Pharmaceuticals include Galmed Pharmaceuticals (GLMD), SCYNEXIS (SCYX), Sonoma Pharmaceuticals (SNOA), Syros Pharmaceuticals (SYRS), Barinthus Biotherapeutics (BRNS), Celularity (CELU), Anebulo Pharmaceuticals (ANEB), Affimed (AFMD), Aadi Bioscience (AADI), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical preparations" industry. NeuroBo Pharmaceuticals vs. Galmed Pharmaceuticals SCYNEXIS Sonoma Pharmaceuticals Syros Pharmaceuticals Barinthus Biotherapeutics Celularity Anebulo Pharmaceuticals Affimed Aadi Bioscience ProPhase Labs NeuroBo Pharmaceuticals (NASDAQ:NRBO) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, community ranking, valuation, analyst recommendations and dividends. Do analysts rate NRBO or GLMD? NeuroBo Pharmaceuticals presently has a consensus target price of $10.00, suggesting a potential upside of 266.30%. Given NeuroBo Pharmaceuticals' higher possible upside, analysts plainly believe NeuroBo Pharmaceuticals is more favorable than Galmed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroBo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Galmed Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the MarketBeat Community prefer NRBO or GLMD? Galmed Pharmaceuticals received 415 more outperform votes than NeuroBo Pharmaceuticals when rated by MarketBeat users. However, 75.00% of users gave NeuroBo Pharmaceuticals an outperform vote while only 63.78% of users gave Galmed Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNeuroBo PharmaceuticalsOutperform Votes2775.00% Underperform Votes925.00% Galmed PharmaceuticalsOutperform Votes44263.78% Underperform Votes25136.22% Is NRBO or GLMD more profitable? Galmed Pharmaceuticals' return on equity of -27.06% beat NeuroBo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets NeuroBo PharmaceuticalsN/A -154.04% -109.08% Galmed Pharmaceuticals N/A -27.06%-23.47% Do insiders & institutionals have more ownership in NRBO or GLMD? 1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 0.5% of NeuroBo Pharmaceuticals shares are owned by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor NRBO or GLMD? In the previous week, NeuroBo Pharmaceuticals had 5 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 7 mentions for NeuroBo Pharmaceuticals and 2 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.34 beat NeuroBo Pharmaceuticals' score of 0.07 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroBo Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Galmed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, NRBO or GLMD? NeuroBo Pharmaceuticals has a beta of -0.28, indicating that its share price is 128% less volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Which has preferable valuation & earnings, NRBO or GLMD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroBo PharmaceuticalsN/AN/A-$12.47MN/AN/AGalmed PharmaceuticalsN/AN/A-$6.91M-$2.40-1.75 SummaryGalmed Pharmaceuticals beats NeuroBo Pharmaceuticals on 8 of the 12 factors compared between the two stocks. Ad InvestorPlace“A very dark day is coming to America”Wall Street Legend on Economy: "If you knew what I know, you'd be terrified too." Something huge is headed to America's shores – and it scares the hell out of Wall St. legend Louis Navellier. When it makes landfall, its impact will be more violent and more severe than any financial crisis we've ever seen… "No matter how prepared you think you are, you aren't prepared enough," he warns.Click here to see his official warning. Get NeuroBo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRBO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRBO vs. The Competition Export to ExcelMetricNeuroBo PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.39M$7.54B$5.58B$8.45BDividend YieldN/A5.49%4.65%4.06%P/E RatioN/A19.70113.6218.69Price / SalesN/A250.171,146.6372.92Price / CashN/A40.1939.3233.61Price / Book0.795.844.914.56Net Income-$12.47M$151.63M$116.99M$225.27M7 Day Performance-17.77%6.61%3.01%2.50%1 Month Performance-18.75%23.42%16.28%12.52%1 Year Performance-22.57%19.17%24.92%21.34% NeuroBo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRBONeuroBo Pharmaceuticals2.9453 of 5 stars$2.73+3.0%$10.00+266.3%-24.8%$13.39MN/A0.008News CoverageGap UpGLMDGalmed Pharmaceuticals1.8111 of 5 stars$4.20-11.2%N/A-18.8%$21.19MN/A-1.7520Analyst ForecastSCYXSCYNEXIS2.468 of 5 stars$1.44+2.1%N/A-35.1%$53.27M$9.67M0.7160News CoverageGap UpSNOASonoma Pharmaceuticals1.2805 of 5 stars$2.78-2.5%N/A+275.7%$52.83M$12.70M-3.81180News CoverageSYRSSyros Pharmaceuticals4.1381 of 5 stars$1.96+1.0%$5.00+155.1%-34.4%$52.55M$9.94M-0.39120Gap UpBRNSBarinthus Biotherapeutics2.3595 of 5 stars$1.33+7.3%$5.83+338.6%N/A$52.43M$800,000.00-0.72107News CoverageGap UpCELUCelularity0.096 of 5 stars$2.65-1.8%N/A+17.2%$51.43M$22.77M0.00220News CoverageGap DownANEBAnebulo Pharmaceuticals2.3539 of 5 stars$1.90-0.5%$8.00+321.1%-40.2%$49.27MN/A-5.134Analyst ForecastGap UpAFMDAffimed4.0346 of 5 stars$3.21-1.5%$20.00+523.1%-31.5%$48.88M$2.68M0.00200Positive NewsAADIAadi Bioscience3.8177 of 5 stars$1.94+1.0%$10.25+428.4%-53.8%$47.64M$23.82M-0.7640News CoverageGap UpPRPHProPhase Labs2.392 of 5 stars$2.46+2.5%$11.00+347.2%-44.0%$46.93M$17.97M-2.28130 Related Companies and Tools Related Companies: Galmed Pharmaceuticals Alternatives SCYNEXIS Alternatives Sonoma Pharmaceuticals Alternatives Syros Pharmaceuticals Alternatives Barinthus Biotherapeutics Alternatives Celularity Alternatives Anebulo Pharmaceuticals Alternatives Affimed Alternatives Aadi Bioscience Alternatives ProPhase Labs Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NRBO) was last updated on 10/5/2024 by MarketBeat.com Staff From Our PartnersKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredThe world’s smartest man is in their crosshairsElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored“A very dark day is coming to America”Wall Street Legend on Economy: "If you knew what I know, you'd be terrified too." Something huge is headed ...InvestorPlace | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroBo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
